Clinical Trials
84 trialsNCT01190930 2026-05-22
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT01946477 2026-05-22
POM MM 014
Celgene
Phase 2 Completed
NCT04895592 2026-05-14
Radiosurgery Before Surgery for the Treatment of Brain Metastases
Emory University
Phase EARLY_PHASE1 Completed
NCT03934684 2026-05-11
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT00558519 2026-04-29
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT06104449 2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01279096 2026-04-22
Vandevol
University Hospital, Lille
Phase 1 Completed
NCT01816971 2026-04-21
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT04996160 2026-04-17
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
Phase 1 Completed
NCT02719613 2026-04-15
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Completed
NCT02203643 2026-04-14
FORTE
University of Turin, Italy
Phase 2 Completed
NCT03984097 2026-04-09
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Completed
NCT02626481 2026-04-07
IFM2014-04
University Hospital, Lille
Phase 2 Completed
NCT01502085 2026-04-03
RZD
Hackensack Meridian Health
Phase 1/2 Completed
NCT01813227 2026-04-03
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Hackensack Meridian Health
Phase 2 Completed
NCT00931645 2026-04-02
Auto-LLC 2001
University Hospital, Caen
Phase 3 Completed
NCT01846390 2026-03-27
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 1 Completed
NCT07493486 2026-03-25
IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
Zhejiang Cancer Hospital
Phase 2 Completed
NCT06136598 2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01615029 2026-03-16
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
NCT01572480 2026-03-10
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
NCT01919086 2026-03-02
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT07425678 2026-02-23
Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients
Aga Khan University
Phase 4 Completed
NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT02776436 2026-02-17
REDEX
Leiden University Medical Center
Phase 1 Completed
NCT00400946 2026-02-13
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Phase 3 Completed
NCT02523976 2026-02-11
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT02858804 2026-02-11
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT04463953 2026-02-11
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
NCT01745640 2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2 Completed
NCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04681105 2026-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Phase 1 Completed
NCT02389517 2026-01-22
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Phase 2 Completed
NCT02969837 2026-01-16
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT02896582 2026-01-14
LyMa101
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02441686 2026-01-13
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04655144 2026-01-07
Dex-Fib
University of Miami
Phase 3 Completed
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT03702725 2026-01-06
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Phase 1 Completed
NCT01665794 2025-12-22
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
Phase 1/2 Completed
NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT02461888 2025-12-17
MUKEight
University of Leeds
Phase 2 Completed
NCT04082962 2025-12-17
Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
Massachusetts Eye and Ear Infirmary
Phase 1 Completed
NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT02473042 2025-12-05
Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
M.D. Anderson Cancer Center
Phase NA Completed
NCT06007586 2025-12-04
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute
Phase 3 Completed
NCT03201965 2025-11-26
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 3 Completed